Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …

Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN)
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Purpose To develop a prognostic system for transplantation-age patients with primary
myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and …

Abstract Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin
(CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to …

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now …

Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by
JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; …

We studied the impact of driver mutations of JAK2, CALR,(calreticulin gene) or MPL on
clinical course, leukemic transformation, and survival of patients with primary myelofibrosis …

Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …

A quarter of patients with essential thrombocythemia or primary myelofibrosis carry a driver
mutation of CALR, the calreticulin gene. A 52-bp deletion (type 1) and a 5-bp insertion (type …